Roche Holding Ltd. (ADR) - RHHBY - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 12, 2013

Roche Holding Ltd. (ADR) - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
RHHBY	Over the counter	2834	http://www.roche.com	63.13 -0.61
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Roche Holding Ltd. (ADR) Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy - May 17th, 2013 5:25 am Good News for Roche's Tarceva - May 16th, 2013 4:00 pm Pipeline Progress at Gilead - May 16th, 2013 11:30 am Melanoma Treatment Harnesses Immune System to Combat Cancer Cells - May 15th, 2013 7:01 pm Cancer Meeting Highlights the Good and Bad of the Immune System - May 15th, 2013 5:10 pm ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors - May 15th, 2013 4:00 pm Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer - May 15th, 2013 4:00 pm ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up - May 15th, 2013 4:00 pm Nektar Posts Wider Loss, Maintains View - May 15th, 2013 9:45 am Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO - May 14th, 2013 11:00 pm FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer - May 14th, 2013 5:14 pm FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer - May 14th, 2013 5:14 pm Companies Invest in Antibodies That Fight Tumors - May 13th, 2013 2:54 pm Lilly Scraps Oncology Candidate - May 13th, 2013 9:00 am Tackling Cancer: Endometrial Cancer's Biggest Current & Upcoming Players - May 11th, 2013 1:00 pm [video] Biotech's Next Big Thing: ASCO - May 9th, 2013 7:39 am Narrower-than-Expected Loss at Seattle Genetics - May 8th, 2013 8:00 am Regeneron Earnings Soar As Eylea Sales Skyrocket - May 3rd, 2013 3:25 pm Narrower-Than-Expected Loss at Incyte - May 3rd, 2013 11:40 am Regeneron Stock Soars On Q1 Results, Guidance Hike - May 3rd, 2013 9:22 am View All Current Headlines >>